N/A N=265 Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a RAD Board
Radiation Exposure to Operator
Primary: Operator Radiation Exposure — .65; .56 mSv
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=170 Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation
Cardiac Catheterization · Radiation Exposure
Primary: Radiation Dose to Primary Operator (RaySafe), Cardiac Catheterization — 18; 39 microsievert
N/A N=197 Radioprotective Light-weight Caps in the Interventional Cardiology Setting
Occupational Exposure to Radiation
Primary: Radiation Attenuation in Percentage (%) — 12; 91.5; 97.1 Percentage
N/A N=55 Radiation Exposure of ERCP Personnel at Different Standing Locations and Different Patient Positions.
Occupational Radiation Exposure
Primary: Effective Radiation Dose — 0.0307; 0.0192 mSv
N/A N=10 Dosimeter Location in Pain Physicians
RAD
Primary: Radiation Readings — 122.8; 158.8; 236.9 mREM
Phase 2 N=45 Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Prostatic Neoplasms
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 41 Participants
N/A N=1,472 Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Participants With Second Primary Malignancies (SPM) — 24 Participants
N/A N=20 Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
N/A N=6,700 Adult and Paediatric Patient Radiation Doses From Multidetector Row Computed Tomography Scans: a National Survey
Cancer
Primary: Value of Mean Volumetric Computed Tomography Dose Index (CTDI Vol) for Head CT Examinations. — 64; 28.7 mGy
N/A N=228 Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells
Coronary Artery Disease · Chest Pain
Primary: Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging — 0.183; 0.159 gamma-H2AX foci in blood lymphocytes — p=<0.05
N/A N=1,000 ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
N/A N=63 Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Local Control — 61 Participants
N/A N=6 Early-Phase Safety of Proton Therapy Equipment
Malignant Glioma · Hepatocellular Carcinoma · Head and Neck Malignant Tumor
Primary: Rate and Severity of Adverse Reactions — 6 participants
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
Phase 3 N=44 Proton/Photon Rt - Benign Meningiomas(P92-13)
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
N/A N=77 A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: The Proportion of Patients for Whom the Intended Treatment Was Feasible — 70 Participants
Phase 2 N=45 Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Urinary Toxicity Assessed by CTCAE v4.0 — 33 Participants
N/A N=12 Effect of High Doses of Radiation on Bone Structure and Metabolism
Malignant Bone Tumors
Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3
N/A N=30 Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
Head and Neck Cancer
Primary: Time Until the Maximum Oral Mucositis Measured From the Start of Radiation Treatment. — 34; 29 Days — p=0.9906
N/A N=23 Internal Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity — 20 participants
N/A N=72 Breast Displacement and CT Radiation Dose
Computed Tomography · Radiation Dosage
Primary: Skin Entrance Radiation Dose During Computed Tomography (CT) — 1775; 1325; 625; 259 mrad
N/A N=1,188 Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation
Cancer
Primary: Percent of Patients Receiving Daily Imaging — 679; 509 Participants
N/A N=74 A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
Biopsy Proven Non Small Cell Lung Cancer · Head and Neck Cancer · Gastrointestinal Cancer
Primary: Tumor Volume — 93.55 cm^3
N/A N=27 UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization
Breast Cancer
Primary: Number of Computed Tomography (CBCTs) a Participant Receives During Radiation Therapy Treatment as Quantified Via Counting the Number Used During the Setup Process. — 2…
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
N/A N=3 Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Cervical Cancer
Primary: Safety - Adverse Event Rate and Severity — 100; 100; 100; 33.3 percentage of participants and severity
Phase 2 N=30 Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
Prostatic Neoplasms
Primary: Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With…
Phase 4 N=5 SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
Carcinoma · Carcinoma, Hepatocellular · Liver Neoplasm
Primary: Mean Absorbed Dose (Gy) for the Whole Body — 0.941 mGy
Phase 2 N=255 Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer · Psychosocial Effects of Cancer and Its Treatment · Radiation Toxicity
Primary: Percentage of Patients With Reduction From Baseline to the One-year EPIC Bowel Domain Score That Exceeds 5 Points — 30.1; 28.0 percentage of participants — p=0.19
Phase 2 N=64 RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
Prostate Cancer
Primary: Progression-free Survival — 10.5; 11.8 Months